Online inquiry

IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11035MR)

This product GTTS-WQ11035MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ERBB2&ERBB3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001005862.3; NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064; 2065
UniProt ID P04626; P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ11035MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3219MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ARGX-110
GTTS-WQ6970MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ5665MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDX-011
GTTS-WQ4976MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA c2G4-N
GTTS-WQ7883MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-249320
GTTS-WQ5618MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP791
GTTS-WQ6469MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CT-P-59
GTTS-WQ14750MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-35
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW